Postoperative nausea and vomiting (PONV) are common complications after gynecologic laparoscopic surgery. In the absence of prophylactic antiemetics, the incidence of PONV may be as high as 40%–77%.1–4 The administration of prophylactic antiemetics, either alone or in combination, have been shown to reduce this incidence. However, the routine administration of antiemetics increases costs and side effects.5,6 Reducing baseline risk has been recommended as an effective strategy for reducing PONV, including using specific anesthetic techniques that minimize the risk of PONV.7,8
Nitrous oxide (N2O) has analgesic and sedative properties,9 but may potentially increase the incidence of PONV.10,11 N2O might increase the incidence of PONV by several potential mechanisms: (1) increase in middle ear pressure12,13; (2) bowel distension, which is controversial.14–16 A meta-analysis revealed that each additional hour of anesthesia using N2O doubles the risk of bowel distension (odds ratio, 2.09; 95% CI: 1.27–3.59) compared with anesthesia using air/oxygen14; (3) activation of the dopaminergic system in the chemoreceptor trigger zone17; and (4) interaction with opioid receptors.18
The evidence on PONV after N2O/volatile anesthetic (enflurane or isoflurane) in gynecologic laparoscopic surgery is controversial. N2O has been demonstrated to increase the incidence of PONV in some studies,10,11,19–22 but not in others.23–26 Most of the studies concerning the influence of N2O on PONV used 60%–70% inspiratory concentration (FI) of N2O. It is not clear if limiting N2O to a lower concentration decreases the risk of PONV. We postulate that the FI of N2O has a dose–response relationship to the incidence of PONV. Our experimental hypothesis is that the incidence of PONV would increase as the FI N2O increases from 50% and 70%, when compared with an air/oxygen (FI O2 30%) control group in gynecologic laparoscopic surgery under general anesthesia.
After IRB approval, written informed consent was obtained from 150 ASA physical status I and II patients, between 19 and 75 yr old, undergoing elective laparoscopic gynecological surgery (removal of ovarian tumors and cysts, myomectomy, laparoscopic-assisted vaginal hysterectomy, and infertility surgery). The exclusion criteria were obesity (body mass index >33 kg/m2), pregnancy, breast-feeding, known hypersensitivity to drugs used in the study protocol, use of antiemetics, psychotropic drugs and steroids within 72 h before surgery. Patients with known comorbidities that could increase the incidence of PONV were also excluded, i.e., diseases which impaired gastric motility (diabetes mellitus, chronic cholecystitis, gastric and intestinal disease, neuromuscular disorders, neuropathies, and liver dysfunction), vestibular disease, history of migraine headache, central nervous system injury, renal impairment, irregular menstrual cycle (duration of <21 or >35 days and/or variations between cycles >4 days), alcoholism, and opioid addiction.
As per standard practice in the hospital, patients received 7.5 mg of midazolam PO 1 h before the surgery with no prophylactic antiemetics. Standard monitoring was applied including electrocardiography, noninvasive arterial blood pressure, pulse oximetry, and capnography.
After induction of anesthesia with thiopental 5 mg/kg and fentanyl 1–2 μg/kg, patients were manually ventilated with oxygen via facemask. Endotracheal intubation was facilitated with vecuronium 0.1 mg/kg IV. Patients were randomized by computer-generated random numbers to receive air and oxygen, FI O2 30% (group G0), 50% N2O and oxygen (group G50) or 70% N2O and oxygen (group G70). Anesthesia was maintained with sevoflurane (end-tidal concentration approximately 1 minimum alveolar concentration) and supplemental bolus doses of fentanyl IV (1 μg/kg) to keep heart rate and arterial blood pressure within 20% of baseline values and additional vecuronium was administered to maintain 1 or 2 twitches on the train-of-four monitor. All patients received 10 mL/kg of crystalloids intraoperatively. Insertion of a nasogastric tube and gastric suction were not used. Neuromuscular blockade was antagonized with neostigmine 2.5 mg and atropine 1 mg IV.
Postoperatively, patients received 1000 mL (5 mL · kg−1 · h−1) of crystalloids. The incidence of postoperative nausea, vomiting (POV) and the use of rescue antiemetics were collected at 2 and 24 h after surgery. The severity of postoperative nausea and pain were evaluated using a 100-mm visual analog scale (VAS) during the first 24 h postoperatively (VAS 0 = no pain/nausea, 100 = maximal pain/nausea). A nausea VAS score was measured for each episode, but the highest score during the early and the late period was used for statistical evaluation. Patients who experienced at least one episode of nausea, POV or retching, or any combination of these during 24 h postoperatively were considered to have had PONV. POV was defined as at least one episode of vomiting or retching that occurred within 24 h postoperatively. PONV was defined as early (within the first 2 h) or late (2–24 h postoperatively). Clinical nurses specifically trained for the study collected the data and were blinded to the anesthesia technique used and randomization. Pain VAS score and total amount of opioids were recorded at 2 h and at 24 h postoperatively. Metoclopramide 10 mg IV was used as the rescue antiemetic. This was the standard clinical practice in the hospital. The administration of rescue antiemetic was based on the following criteria: patients who had 2 or more episodes of POV or retching within a period of 30 min, nausea lasting more than 15 min or nausea VAS score 50 mm or more, or when a patient requested treatment. Diclofenac 75 mg IM was given immediately after surgery and, if needed, 12 h later. For severe pain (VAS score >40 mm), meperidine 25 mg up to 100 mg IV was used. All patients remained in the hospital for at least 24 h, as was our standard practice for laparoscopic gynecological surgery.
Calculation of sample size was based on preliminary data collected at General Hospital Zadar, Zadar, Croatia.27 We determined that 45 patients per group would be sufficient to demonstrate a reduction of PONV by 20% from G70 to G50 and by 20% from G50 to G0 with a power of 0.8 and α < 0.05. The expected incidence of PONV at 24 h for the three groups was G0 = 30%, G50 = 50%, and G70 = 70%. The data were analyzed using the statistical program SAS 8.2. Quantitative values were compared using Kruskal-Wallis test and Mann-Whitney U-test with correction for multiple comparisons among groups. Categorical data were analyzed by Pearson χ2 test or Fisher’s exact test with correction for multiple comparisons as appropriate. Data were expressed as number or percentages and mean ± sd. A P value of <0.05 was considered statistically significant.
Of 150 patients, 137 completed the study (G0 = 46, G50 = 46, and G70 = 45). Thirteen patients were excluded from the analysis. Four patients were excluded in group G0: one patient was treated with corticosteroids for urticaria at induction of anesthesia, one patient had an anesthesia time <30 min, two patients had a protocol violation. Four patients were excluded in group G50: 1 patient had a conversion to laparotomy, 1 patient’s anesthesia time was <30 min, and 2 patients had a protocol violation. Five patients were excluded in group G70: 2 patients’ surgery was converted to laparotomy, 1 patient each had severe hypotension after induction, which lasted more than 5 min, acute coronary syndrome postoperatively, and anesthesia time <30 min.
There was no difference among groups regarding age, weight, height, body mass index, ASA physical status, smoking status, history of motion sickness and/or PONV, phase of menstrual cycle, thiopental dose, duration of anesthesia and surgery, and type of surgery (Table 1).
There was an overall difference in the incidence of PONV for 24 h after surgery among the groups (P = 0.018) (Table 2). Group G0 was significantly different from group G70 (P = 0.018), but no difference was noted between groups G0 and G50 (P = 0.855) or G50 and G70 (P = 0.426) (Table 2). Although there was a trend towards an increase in the incidence of early PONV (2 h postoperatively) and the late postoperative period (2–24 h) with increasing N2O concentration, this did not reach statistical significance, P = 0.071 and 0.437, respectively (Table 2). The incidence of nausea showed a similar significant difference, with P = 0.012, but the incidence of POV was not different among the groups, although there was a trend (Table 2). The severity of nausea was significantly increased with increasing N2O concentration. There was no difference in the need for rescue antiemetic (Table 2), pain scores or opioids consumption among the groups (at 2 and 24 h after surgery) (Table 3).
This study demonstrates that N2O, when administered with oxygen and sevoflurane, increases the incidence of postoperative nausea. The preliminary findings indicate that N2O may increase PONV in a dose–response fashion. The FI of 70% N2O significantly increases the incidence of PONV at 24 h, nausea at 24 h, and nausea VAS scores when compared with no N2O. In contrast, FI of 50% N2O did not cause significantly increased PONV, nor nausea at 24 h compared with only oxygen/air.
We chose 50% and 70% N2O in this study because of their clinical relevance. FI of N2O lower than 50% is rarely used in anesthesia practice. The FI of 50% N2O was chosen because it is generally perceived by anesthesiologists that this concentration minimally affects the incidence of PONV.28 However, there are no data to support that assumption. N2O 70% was selected as it represents the highest concentration of N2O used in clinical anesthesia practice.
All the reported studies on PONV after N2O/volatile anesthetic (enflurane or isoflurane) in gynecologic laparoscopic surgery compared a single FI of N2O, usually in the range of 66%–70%, with control.20,21,23,24 The results from this study agree with those of Felts et al. who demonstrated that PONV is increased from 9.3% in air/oxygen (FI O2 33%) to 29.2% with 66% of N2O in oxygen after enflurane anesthesia for outpatient gynecologic laparoscopy (P < 0.001).21 Contrary to our study, Hovorka et al. did not find significant differences in the incidence of PONV among three groups of patients anesthetized with either isoflurane or enflurane with 70% N2O in oxygen, and isoflurane without N2O, after gynecological laparoscopy.23 This discrepancy could be explained by the different duration of the anesthesia (the mean anesthesia times among groups were 37–40 min in Hovorka et al.’s study and 70–76 min in our study). One of the mechanisms of N2O-induced nausea and vomiting might be related to middle ear pressure. The longer duration of N2O exposure, as in our study, likely caused a larger increase in middle ear pressure as the time to reach peak middle ear pressure is about 60 min after the introduction of N2O and about 30 min to return to baseline after N2O is discontinued.12 Also, in Hovorka et al.’s study, smoking status was unknown, which could have biased the results.
Lonie and Harper found a significant increase only in the incidence of POV between study groups (from 17% without N2O to 49% with N2O 67% in oxygen after enflurane anesthesia), but not nausea.20 This could have been due to the more frequent administration of rescue antiemetic in our study. We treated our patients who had severe nausea and patients who vomited (22% of patients in both groups with N2O and 15% in the group without N2O). However, only a few patients were treated in Lonie and Harper’s study (7.5% patients in the N2O group and 7.1% in the group without N2O). Sengupta and Plantevin reported results similar to Lonie and Harper, but their study was under-powered, with a smaller number of patients (64), which resulted in a nonstatistically significant difference between the N2O group and oxygen group, 33% versus 12.9%, respectively.24
Results from the IMPACT study suggest that omitting N2O in a multimodal PONV prophylaxis strategy further decreases the incidence of PONV by about 12%, if a volatile anesthetic is used.29 However, the study did not address the dose–response relationship of N2O. The preliminary results from our study, which showed that 70% N2O increases the incidence of nausea concur with the IMPACT study and a meta-analysis.10,29 Although our initial power analysis was expected to provide adequate power to demonstrate a dose–response, our actual results showed a smaller than expected difference. Assuming that this trend in the incidence of PONV at 24 h were to persist, a study with a sample size of 221 patients in each group would have been necessary to produce a statistically significant difference among each of the three groups with a power of 0.8 and α < 0.05. Using the same assumption, it would require 410 patients per group to show a significant difference in the incidence of nausea at 24 h, and 691 patients per group for the incidence of POV at 24 h. The value of this study is that it provides preliminary data that indicate that N2O may increase PONV in a dose–response fashion. We feel it would be valuable if a large prospective study were performed to confirm if 50% N2O causes a lower incidence of PONV than 70% N2O.
There are several limitations to our study. We can be criticized for not administering a prophylactic antiemetic or combination strategy given the high-risk nature of this surgical population for PONV. We, however, wanted to specifically investigate the dose–response effect of N2O, which may have been masked by the use of prophylactic antiemetics. The difference in N2O concentrations among the groups also means that the FI O2 was different in groups G50 and G70. High FI O2 (0.8) has been shown to reduce the incidence of PONV.30,31 However, more recent studies have cast doubt on previous findings. Purhonen et al., in ambulatory gynecological laparoscopic patients, showed that supplemental oxygen does not reduce the incidence of PONV.32 The authors compared FI O2 30% and FI O2 80% with additional O2 in the postanesthesia care unit up to 1 h, but did not find a difference in the PONV incidence after 24 h, 62% versus 55%, respectively. Our study had only a 20% difference in FI O2 among the groups compared with a 50% difference in Purhonen et al.’s study, and we did not use supplemental O2 in the postanesthesia care unit. Therefore, the impact of O2 in our study is likely to be small, if any. Furthermore, a large study involving 560 patients investigating the impact of O2 on PONV concluded it has no impact on PONV regardless of the site or surgery or the observational period (early or late PONV).33
In conclusion, we demonstrated that 70% N2O increases the incidence of nausea and severity of nausea at 24 h after laparoscopic gynecological surgery in the absence of any prophylactic antiemetic. This preliminary finding indicates that N2O may increase PONV in a dose-dependent fashion. A study with a sample size of >400 patients in each group would be necessary to produce a statistically significant difference among groups with no N2O, 50% N2O, and 70% N2O. We do not recommend using high concentrations of N2O in this clinical setting.
1. Gan TJ, Franiak R, Reeves J. Ondansetron orally disintegrating tablet versus placebo for the prevention of postdischarge nausea and vomiting after ambulatory surgery. Anesth Analg 2002;94:1199–200
2. Eriksson H, Korttila K. Recovery profile after desflurane with or without ondansetron compared with propofol in patients undergoing outpatient gynecological laparoscopy. Anesth Analg 1996;82:533–8
3. Boehler M, Mitterschiffthaler G, Schlager A. Korean hand acupressure reduces postoperative nausea and vomiting after gynecological laparoscopic surgery. Anesth Analg 2002;94:872–5
4. Scuderi PE, James RL, Harris L, Mims GR. Multimodal antiemetic management prevents early postoperative vomiting after outpatient laparoscopy. Anesth Analg 2000;91:1408–14
5. Scholz J, Steinfath M, Tonner PH. Postoperative nausea and vomiting [Review article]. Curr Opin Anaesthesiol 1999;12:657–61
6. Allan BTW, Smith I. Cost considerations in the use of anaesthetic drugs. Curr Opin Anaesthesiol 2002;15:227–32
7. Yang H, Choi PT-L, McChesney J, Buckley N. Induction with sevoflurane-remifentanil is comparable to propofol-fentanyl-rocuronium in PONV after laparoscopic surgery. Can J Anaesth 2004;51:660–7
8. Gan TJ, Meyer T, Apfel CC, Chung F, Davis PJ, Eubanks S, Kovac A, Philip BK, Sessler DI, Temo J, Tramèr MR, Watcha M. Consensus guidelines for managing postoperative nausea and vomiting. Anesth Analg 2003;97:62–71
9. Michael J. Nitrous oxide: still useful in the year 2000? [Review article] Curr Opin Anaesthesiol 1999;12:461–6
10. Tramèr M, Moore A, McQuay H. Omitting nitrous oxide in general anaesthesia: meta-analysis of intraoperative awareness and postoperative emesis in randomized controlled trials. Br J Anaesth 1996;76:186–93
11. Hartung J. Twenty-four of twenty-seven studies show a greater incidence of emesis associated with nitrous oxide than with alternative anesthetics. Anesth Analg 1996;83:114–16
12. Karabiyik L, Bozkirli F, Çelebi H, Göksu N. Effect of nitrous oxide on middle ear pressure: a comparison between inhalational anaesthesia with nitrous oxide and TIVA. Eur J Anaesthesiol 1996;13:27–32
13. Nader ND, Simpson G, Reedy RL. Middle ear pressure changes after nitrous oxide anesthesia and its effect on postoperative nausea and vomiting. Laryngoscope 2004;114:883–6
14. Orhan-Sungur M, Apfel C, Akça O. Effects of nitrous oxide on intraoperative bowel distension. Curr Opin Anaesthesiol 2005;18:620–4
15. Pedersen FM, Wilken-Jensen C, Knudsen F, Lindekaer AL, Svare EI. The influence of nitrous oxide on recovery of bowel function after abdominal hysterectomy. Acta Anaesthesiol Scand 1993;37:692–6
16. Akça O, Lenhardt R, Fleischmann E, Treschan T, Greif R, Fleischhackl R, Kimberger O, Kurz A, Sessler DI. Nitrous oxide increases the incidence of bowel distension in patients undergoing elective colon resection. Acta Anaesthesiol Scand 2004;48:894–8
17. Murakawa M, Adachi T, Nakao S, Seo N, Shingu K, Mori K. Activation of the cortical and medullary dopaminergic systems by nitrous oxide in rats: a possible neurochemical basis for psychotropic effects and postanesthetic nausea and vomiting. Anesth Analg 1994;78:376–81
18. Ohashi Y, Guo T, Orii R, Maze M, Fujinaga M. Brain stem opioidergic and GABAergic neurons mediate the antinociceptive effect of nitrous oxide in Fischer rats. Anesthesiology 2003;99:947–54
19. Divatia JV, Vaidya JS, Badwe RA, Hawaldar RW. Omission of nitrous oxide during anesthesia reduces the incidence of postoperative nausea and vomiting: a meta-analysis. Anesthesiology 1996;85:1055–62
20. Lonie DS, Harper NJ. Nitrous oxide anaesthesia and vomiting. The effect of nitrous oxide anaesthesia on the incidence of vomiting following gynaecological laparoscopy. Anaesthesia 1986;41:703–7
21. Felts JA, Poler SM, Spitznagel EL. Nitrous oxide, nausea and vomiting after outpatient gynecologic surgery. J Clin Anesth 1990;2:168–71
22. Chanvej L, Kijsirikul S, Thongsuksai P, Naheem L. Post-operative nausea and vomiting in out-patient gynecologic laparoscopy: a comparison of thiopental–nitrous oxide, propofol-nitrous oxide and total intravenous anesthesia using propofol. J Med Assoc Thai 2001;84:697–704
23. Hovorka J, Korttila K, Erkola O. Nitrous oxide does not increase nausea and vomiting following gynaecological laparoscopy. Can J Anaesth 1989;36:145–8
24. Sengupta P, Plantevin OM. Nitrous oxide and day-case laparoscopy: effects on nausea, vomiting and return to normal activity. Br J Anaesth 1988;60:570–3
25. Sukhani R, Lurie J, Jabamoni R. Propofol for ambulatory gynecologic laparoscopy: does omission of nitrous oxide alter postoperative emetic sequelae and recovery? Anesth Analg 1994;78:831–5
26. Arellano RJ, Pole ML, Rafuse SE, Fletcher M, Saad YG, Friedlander M, Norris A, Chung FFT. Omission of nitrous oxide from a propofol-based anesthetic does not affect the recovery of women undergoing outpatient gynecologic surgery. Anesthesiology 2000;93:332–9
27. Šimurina T, Mraović B, Sonicki Z. Incidence of PONV: Is 50% nitrous oxide friend or foe? Anesthesiology 2006;105:A1401
28. Eger EI II. Volatile anesthetics for the new millennium. Audiodigest Anesthesiol 2000;42:15
29. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med 2004;350:2441–51
30. Greif R, Laciny SS, Rapf B, Hickle RS, Sessler DI. Supplemental oxygen reduces the incidence of postoperative nausea and vomiting. Anesthesiology 1999;91:1246–52
31. Goll V, Akça O, Greif R, Freitag H, Arkilic C, Scheck T, Zoeggeler A, Kurz A, Krieger G, Lenhardt R, Sessler D. Ondansetron is no more effective than supplemental intraoperative oxygen for prevention of postoperative nausea and vomiting. Anesth Analg 2001;92:112–17
32. Purhonen S, Turunen M, Ruohoaho U-M, Niskanen M, Hynynen M. Supplemental oxygen does not reduce the incidence of postoperative nausea and vomiting after ambulatory gynecologic laparoscopy. Anesth Analg 2003;96:91–6
© 2008 International Anesthesia Research Society
33. Turan A, Apfel CC, Kumpch M, Danzeisen O, Eberhart LHJ, Forst H, Heringhaus C, Isselhorst C, Trenkler S, Trick M, Vedder I, Kerger H. Does the efficacy of supplemental oxygen for the prevention of postoperative nausea and vomiting depend on the measured outcome, observational period or site of surgery? Anaesthesia 2006;61:628–33